Brussels, Belgium and Baltimore, Maryland, 30 June, 2013 – Both UCB and the Lieber Institute for Brain Development (LIBD) are committed to innovation and collaboration to help people living with severe brain disorders. As such, they are entering a strategic collaboration for the discovery of new drug candidates for treating patients suffering from cognitive impairment.
The research alliance between LIBD and UCB reflects UCB’s “open innovation” approach that aims to generate new knowledge and capitalize on external scientific advances and expertise that complement the company’s unique internal capabilities and skills.
UCB and LIBD will jointly generate novel lead compounds and further optimize them starting from chemical compounds provided by both partners. In addition, the specific interdisciplinary structure of LIBD will bring to the collaboration its unique expertise in translating basic research and drug discovery into effective clinical proof of concept.
Financial details of the collaboration were not disclosed.
Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB said: “This new partnership combines UCB’s world-class Central Nervous System research teams with the Lieber Institute for Brain Development’s unique understanding of basic genetic and molecular mechanisms of developmental brain disorders. Together, the two parties will embark on a mission to discover new medicines that aim to transform the lives of people living with severe diseases.”
“The Lieber Institute for Brain Development was established with historic philanthropic investment to create a new landscape for research about developmental brain disorders and to translate our understanding into changing the lives of affected individuals,” said Daniel Weinberger, Director and CEO of LIBD.
“The partnership with UCB will advance this mission by providing new tools for scientific discovery and by developing new therapeutic agents.”
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
About the Lieber Institute For Brain Development (LIBD)
LIBD, Baltimore, Maryland (www.libd.org) is a private non-profit academic research organization affiliated with the Johns Hopkins University School of Medicine. It is the only institution in the world focused on understanding the neurodevelopmental origins of schizophrenia and related developmental brain disorders and translating this understanding into improving the lives of affected individuals. Founded in 2010 through the philanthropy of the Lieber Family of New York, and the Maltz Family Foundation, LIBD’s core mission is to understand the etiology, prevention and treatment of developmental neuropsychiatric disorders.
For further information UCB
France Nivelle, Global Communications UCB T +32.2.559.9178, firstname.lastname@example.org
Laurent Schots, Media Relations, UCB
T +32.2.559.9264, email@example.com
Antje Witte, Investor Relations UCB T +32.2.559.9414, firstname.lastname@example.org
For further information the Lieber Institute for Brain Development (LIBD)
Tara Eskandari, Chief Administrative Officer/Industry Partnerships
T 410-955-0458, Tara.Eskandari@libd.org
Jean DuBose, Media/Communications
T 410-955-0677, Jean.Dubose@libd.org
Thomas Hyde, M.D.,Ph.D, Chief Operating Officer
T 410-955-0443, Thomas.Hyde@libd.org
Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.